
Conference Coverage
about 4 hours ago
Overcoming SDOH Barriers in Cancer Care: Susan Escudier, MDabout 12 hours ago
Hormone Therapy for Menopause: Timing, Safety, and Best Candidatesabout 12 hours ago
Guidelines for Bronchiectasis Highlight Multiple Treatment MethodsLatest Content

Mapping the Genetic Evolution of MPNs from Chronic to Blastic Phase

Venetoclax Combo Achieves Mixed Results in Relapsed/Refractory Multiple Myeloma

LAG-3 May Be Key SCLC Biomarker

Many US Health Care Workers Face Poverty, Food Insecurity, and Housing Instability

Ongoing COVID-19 Circulation Linked to Increases in Health-Related Work Absences, Workforce Exits

Shorts










Podcasts
Center on Health Equity & Access
Continuing Medical Education
All News

Meta-analyses presented at the CHEST 2025 Annual Meeting find that combinations that include amivantamab and nivolumab improved overall and progression-free survival in non–small cell lung cancer (NSCLC).

The efficacy of GLP-1 inhibitors in weight loss has introduced them as a means of also addressing obstructive sleep apnea in sleep medicine.

Experts also explained how hormone therapy can benefit women managing chronic conditions such as diabetes and hypertension on top of their menopause.

A session held during the CHEST 2025 Annual Meeting focused on the North American guidelines for treating bronchiectasis.

IO Biotech's immune-modulatory cancer vaccine combination shows promise in advanced melanoma, despite missing statistical significance for PFS.

Physician burnout rates have decreased since the pandemic, but the likelihood of Medicare exits threatens access to underserved populations.

A study reveals disparities by sex, socioeconomic status, and location for colorectal cancer screenings.

Telehealth medication abortion service requests double after the Supreme Court's Dobbs ruling, as patients seek accessible and cost-beneficial care.

Researchers will present new findings on how menopause affects cardiovascular, brain, metabolic, and digestive health.

Perioperative enfortumab vedotin plus pembrolizumab demonstrated significant results in a population that represents roughly half of all patients with MIBC, explained Christof Vulsteke, MD, PhD.